PLX
Protalix Restates Stock Incentive Plan
Protalix BioTherapeutics filed an 8-K to amend and restate its 2006 Stock Incentive Plan, effective June 25, 2026, to provide updated rewards for employees and directors.
PLX news
Latest 2 stories · newest Jun 25, 2026
PLX
Protalix presents corporate overview highlighting Elfabrio commercialization strategy
Protalix BioTherapeutics released a corporate presentation dated May 2026 outlining its rare disease treatment pipeline and Elfabrio commercialization plans. The filing includes forward-looking statements regarding cash runway and product commercialization, with risks related to Elfabrio's market ac…
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same PLX feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/PLX/newsSTART FREE